Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow
Executive Summary
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.
You may also be interested in...
Biocon Biologics Reaches Landmark Sales Figure As IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
Biocon Biologics Reaches Landmark Sales Figure; IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.